



May 2, 2017

## Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017

REDWOOD CITY, Calif., May 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results. The call and webcast will follow the release of the first quarter financial results after market close.

### Conference Call Details

To access the live conference call on May 9 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada, or +1 (224) 357-2389 internationally. The conference call ID is 10366777. Please dial in approximately ten minutes prior to the start of the call.

To access the live and subsequently archived webcast of the presentation, go to the [Investor Relations](#) section of the company's web site at <http://investor.genomichealth.com>. Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

### About Genomic Health

[Genomic Health](#), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ<sup>®</sup> Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ<sup>®</sup> Liquid Select<sup>™</sup>. The company is based in [Redwood City](#), California, with international headquarters in Geneva, Switzerland. For more information, please visit, [www.GenomicHealth.com](http://www.GenomicHealth.com) and follow the company on Twitter: [@GenomicHealth](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the other risks set forth in the company's filings with the Securities and Exchange Commission, including our most recent report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.*

*NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.*

GHDX-F



To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/genomic-health-to-announce-first-quarter-2017-financial-results-and-host-conference-call-on-tuesday-may-9-2017-300448235.html>

SOURCE Genomic Health, Inc.

